Halozyme Therapeutics, Inc. (NASDAQ: HALO) has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), co-formulated with ENHANZE, Halozyme’s proprietary recombinant human hyaluronidase enzyme (rHuPH20). This approval marks a new era for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP), introducing the […]
Halozyme Therapeutics, Inc. has entered a pivotal global collaboration and non-exclusive licensing agreement with Acumen Pharmaceuticals. This partnership focuses on utilizing Halozyme’s ENHANZE drug delivery technology to potentially transform the administration of Acumen’s Alzheimer’s treatment. Groundbreaking Approach to Alzheimer’s Treatment Administration The agreement details include an initial payment by Acumen to Halozyme, alongside the possibility […]
Halozyme Therapeutics, a California-based publicly-listed biotech company, has agreed to acquire New Jersey-based specialty pharma company Antares Pharma for around $960 million with an objective to create a specialty product and drug delivery major. As per the terms of the deal, shareholders of the publicly-listed Antares Pharma will be paid $5.6 per share in cash. […]
